Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: OTC labeling

This article was originally published in The Tan Sheet

Executive Summary

OTC labeling: Protocol for FDA's upcoming consumer comprehension study on analgesic alcohol warning label statements should be released by the agency for public comment, the Aspirin Foundation of America suggests in July 22 comments to the agency. FDA announced its plans to conduct alcohol warning and statement of identity label comprehension studies in a May Federal Register notice ("The Tan Sheet" June 2, p. 8). AFA asks that the alcohol warnings message be "appropriate to both the product and the risk" and be designed "to avoid unnecessarily frightening persons who use aspirin to prevent heart attacks or strokes away from the medication." Bayer endorses the association's comments...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087404

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel